source
- STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsAlnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.STAT · 1mo ago↗ source
- STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading dataHighmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.STAT · 1mo ago↗ source
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.BioPharma Dive